Evoke Pharma (EVOK)

Overall impact
B (73)

Commentary

Evoke Pharma is a strong overall performer. With a 'B' rating of 73.0 for overall impact (86th percentile compared to all companies), Evoke Pharma ranks 9th out of 33 industry peers, behind Adamas Pharmaceuticals, Zynerba Pharmaceuticals, Stem Holdings, Inc. and 5 others, and ahead of Zoetis, Ironwood Pharmaceuticals, Aprea Therapeutics and 21 others. On top material causes for Evoke Pharma's industry (Pharmaceuticals & Biotech), Evoke Pharma performs well in Improved Mental Health (84.2 score), Child and Maternal Health (95.0), Child and Maternal Health (93.0) and 5 other causes where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (17.4 score) and Sustainable Use of Natural Resources (38.4).
Impact
Cause EVOK
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
3
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ca, United States
Share classes
EVOK
Description
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California.
Material causes
Ethos considers the following causes material for Evoke Pharma, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.